Last reviewed · How we verify
Linolenate (linolenic acid)
At a glance
| Generic name | linolenic acid |
|---|---|
| Drug class | linolenic acid |
| Target | Fatty acid-binding protein, heart, Free fatty acid receptor 1, Peroxisome proliferator-activated receptor delta |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Lower Doses of Colonic Nutrient Supplementation on Appetite Hormones and Food Intake in Obese Adults (NA)
- ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults (PHASE2)
- The Effect of Alpha Linolenic Acid Intake on Patients With Elevated Glycemic Status (NA)
- Efficacy of Diet on Quality of Life in Multiple Sclerosis (NA)
- Functional Yogurt Consumption and Its Effects on the Lipid Profile of Healthy Subjects (NA)
- Anti-Inflammatory Diet in BRC Patients on Aromatase Inhibitors (NA)
- Gamma-linolenic Acid Supplementation Study (NA)
- Alpha-Linolenic Acid and Inflammatory Markers (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Linolenate CI brief — competitive landscape report
- Linolenate updates RSS · CI watch RSS
- portfolio CI